Isomorphic Software – Trademark Portfolio
Entity Type: 03
Isomorphic Software holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include REIFY and ISOMORPHIC SOFTWARE. The owner is based in San Francisco, CA.
Suite 3500
1 Sansome Street
San Francisco, CA 94104
Showing of trademarks Trademarks
Trademark Classifications
Isomorphic Software's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does Isomorphic Software have?
Isomorphic Software has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.
What trademark classes does Isomorphic Software file in?
Isomorphic Software files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Isomorphic Software's most well-known trademarks?
Isomorphic Software's registered trademark portfolio includes well-known marks such as REIFY and ISOMORPHIC SOFTWARE. These are among 2 currently registered trademarks in the portfolio.
What is Isomorphic Software's trademark registration success rate?
Isomorphic Software has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.